

# 8th Annual Middle Tennessee Antimicrobial Stewardship Symposium

Jointly Provided by Tennessee Medical Association and  
Belmont University College of Pharmacy & Health Sciences

**Friday, May 17, 2024**  
8:00am-4:00pm (CDT)  
Belmont University, Nashville, TN

**Target Audience:** Antimicrobial Stewardship Nurses, Pharmacists, Physicians,  
and Infection Preventionists

**Up to 5.25 contact hours of Live CE Available**  
for nurses, pharmacists, and physicians  
from ACCME & ACPE for these Knowledge-based CE Activities  
\*Nurses may earn up to 5.25 pharmacotherapeutic contact hours

**Deadline to Register: May 5, 2024 (11:59pm CDT)**

Registration is limited to the first 175 registrants

**\$100** - General Registration

**\$75** - Belmont Faculty/Preceptors/Alumni

**\$50** - Students, Residents, Fellows (No CE Credit Awarded)

[Register Here](#)

## Keynote Lecture

### Navigating the Future:

### Artificial Intelligence Applications in Antimicrobial Stewardship

### Whitney Buckel, PharmD, BCIDP

System Antimicrobial Stewardship Pharmacist Manager; Associate Professor of Research,  
Intermountain Health, Pharmacy Services; Salt Lake City, UT

**Policies** for refunds & cancellations, as well as requirements for successful completion of the CE activities and subsequent awarding of credit, can be found on [page 7](#).

**Disclosures:** Individual speaker disclosures are noted in the presentation details on [pages 2-6](#). All relevant financial relationships have been mitigated. No planners or content reviewers have relevant financial relationships with ineligible companies to disclose.

**Exhibiting Supporters:** Abbvie, bioMerieux, Cepheid, Ferring Pharmaceuticals, Karius, Merck, Option Care Health, Pfizer, Shionogi, T2 Biosystems

**This project is funded under a Grant Contract** with the State of Tennessee.

## Symposium Learning Objectives

At the end of this symposium, learners should be able to:

- Discuss how to appropriately utilize current literature to maximize stewardship impact in your facility
- Identify resources available to assist in the development and maintenance of antimicrobial stewardship programs
- Discuss optimization of antimicrobial therapy for certain infections based on evidence-based medicine and local susceptibility information

## **Program Agenda**

**All times are Central Daylight Time (CDT)**

**7:15-8:00am**                      **Registration & Exhibitor Engagement**

**8:00-8:15am**                      **Welcome**

**8:15-9:00am**



### **A Fun-guide to Antifungals**

*(0.75 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-23-021-L04-P)*

**Erin K. McCreary, PharmD, BCPS, BCIDP**; Director of Infectious Diseases Improvement and Clinical Research Innovation, UPMC Clinical Assistant Professor of Medicine, University of Pittsburgh

*Dr. McCreary has no relevant financial relationships to disclose.*

#### **Learning Objectives:**

1. Identify optimal methods for incorporating azole TDM into clinical practice
2. Describe therapeutic goals for safety and efficacy for azole antifungal drug monitoring
3. List the antifungal agents in the drug development pipeline

**9:00-9:45am**



### **Emerging multi-drug resistant Gram-negative rods & determining antimicrobial resistance mechanisms based on susceptibility profile**

*(0.75 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-23-016-L01-P)*

**Ryan Shields, PharmD, MS**; Associate Professor of Medicine, Division of Infectious Diseases; Co-Director, Antibiotic Management Program, University of Pittsburgh Cystic Fibrosis Research Center

*Dr. Shields is a consultant for Cidara, Shionogi, Menarini, Melinta, Merck, Entasis, Utility, Venatorx and has received investigator-initiated research funding from Merck, Melinta, Shionogi, Venatorx, Roche. All relevant financial relationships have been mitigated.*

#### **Learning Objectives:**

1. Identify the most common multidrug-resistant Gram-negative pathogens in the US
2. Select appropriate treatment options based on underlying mechanism of resistance
3. Determine the most likely mechanism of resistance based on a phenotypic susceptibility profile

**9:45-10:05am**

**Break (Sponsored by T2 Biosystems, Inc.) & Exhibitor Engagement**

**10:05-10:50am**



### **Antimicrobial Stewardship in Immunocompromised Patients**

*(0.75 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-23-014-L99-P)*

**Erica Stohs, MD, MPH**; Assistant Professor, Division of Infectious Diseases; Associate Medical Director, Antimicrobial Stewardship Program, Department of Internal Medicine, University of Nebraska Medical Center; Omaha, NE

*Dr. Stohs has received investigator-initiated research funding from Merck & bioMerieux. All relevant financial relationships have ended and have been mitigated.*

#### **Learning Objectives:**

1. Explain the need for antimicrobial stewardship in immunocompromised patients
2. Identify clinical scenarios when antimicrobial stewardship interventions can be implemented
3. Recognize the gaps in the literature and needs for future stewardship in immunocompromised populations

**Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)**

# **Program Agenda**

**All times are Central Daylight Time (CDT)**

**10:50-11:50am**



## **KEYNOTE PRESENTATION**

### **Navigating the Future: Artificial Intelligence Applications in Antimicrobial Stewardship**

*(1.0 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-23-010-L04-P)*

**Whitney Buckel, PharmD, BCIDP**; System Antimicrobial Stewardship Pharmacist Manager, Associate Professor of Research, Intermountain Health, Pharmacy Services

*Dr. Buckel has no relevant financial relationships to disclose.*

#### **Learning Objectives:**

1. Describe artificial intelligence (AI) and machine learning (ML)
2. Characterize applications of AI and ML in infectious diseases related to diagnosis, treatment, and antimicrobial resistance, including their potential benefits and risks
3. Determine potential applications where AI and ML could augment antimicrobial stewardship programs, including but not limited to: empiric antibiotic selection, audit and feedback, antimicrobial use assessment, and predicting or preventing antimicrobial toxicities.

**11:50am-1:00pm**

#### **Lunch & Exhibitor Engagement**

**1:00-1:30pm**

#### **Poster Session & Exhibitor Engagement**

No CE credit available for Poster Session. Poster details will be listed in the Symposium program booklet distributed on the day of the Symposium.

**1:30-2:30pm**

#### **Panel Discussion** (Details are on [p. 4](#)) **and Raffle Prize Drawing**

**2:30-2:45pm**

#### **Break & Go to Roundtable Rooms**

**2:45-3:15pm**

#### **Roundtable Session #1** (Roundtable topics are listed on [pp. 5-6](#))

**3:15-3:20pm**

Rotate to Next Roundtable Session

**3:20-3:50pm**

#### **Roundtable Session #2** (Roundtable topics are listed on [pp. 5-6](#))

**3:50-4:00pm**

Return to Main Conference Room

**4:00pm**

#### **Closing Remarks & Raffle Prize Drawing**

Policies for refunds and cancellations, as well as requirements for successful completion of the CE activities & subsequent awarding of credit can be found on [page 7](#).

**Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)**

## PANEL DISCUSSION

1:30-2:30pm (CDT)

### 1.0 Pharmacotherapeutic Contact Hour

#### Mythbusting Infectious Disease Myths

(1.0 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-008-L01-P )

In this panel discussion, will address myths associated with clinical practice of Infectious Disease. Panel discussants will explain each topic (myth) in detail with the goal to achieve better antimicrobial practices through education.

#### Learning Objectives

1. Describe literature regarding concomitant use of linezolid and selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs)
2. Recall evidence for the role of oral beta lactam antibiotics for blood stream infections
3. Compare & contrast the historical and current data for appropriate antibiotic use in pediatric and CNS infections

#### Moderator

**Matthew Lokant, MD**; Chief Fellow, Infectious Diseases, Vanderbilt University Medical Center; Nashville, TN

#### Panel Discussants

1. **Brittany Lehrer, MD**; Fellow, Vanderbilt University Medical Center, Nashville, TN
2. **Erin K. McCreary, PharmD, BCPS, BCIDP**; Director of Infectious Diseases Improvement and Clinical Research Innovation, UPMC Clinical Assistant Professor of Medicine, University of Pittsburgh
3. **Ryan Shields, PharmD, MS**; Assistant Professor of Medicine, Division of Infectious Diseases; Co-Director, Antibiotic Management Program, University of Pittsburgh Cystic Fibrosis Research Center
4. **Joshua Stripling, MD**; Associate Professor, Director, Antimicrobial Stewardship, Division of Infectious Diseases; Heersink School of Medicine, The University of Alabama at Birmingham

*Dr. Shields is a consultant for Cidara, Shionogi, Menarini, Melinta, Merck, Entasis, Utility, Venatorx and has received investigator-initiated research funding from Merck, Melinta, Shionogi, Venatorx, Roche. All relevant financial relationships have been mitigated. All other panel discussants and the moderator have no relevant financial relationships to disclose.*

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

## ROUNDTABLE SESSIONS

**2:45-3:15pm (CDT) & 3:20-3:50pm CDT)**

Learners may attend one (1) roundtable per session.

Capacity limits will be set for each roundtable. Please select at least one (1) back-up roundtable per session.

1. **Diversity, Equity, Inclusion in Antimicrobial Stewardship and Prescribing**

*(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-013-L04-P)*

**Christopher Evans, PharmD, BCPS**, Healthcare-Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, Nashville, TN

*Dr. Evans has no relevant financial relationships to disclose.*

**Learning Objectives**

- Define diversity, equity, inclusion, and justice as they relate to healthcare
- Describe how antibiotic prescribing is affected by social determinants of health

2. **Beyond Antibiotics: Proactive Measures for MDRO Prevention**

*(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-010-L05-P)*

**Missy Travis, MSN, RN, CIC**; IP&C Consulting, LLC; Nashville, TN

*Ms. Travis is a consultant for Applied Silver. All relevant financial relationships have been mitigated.*

**Learning Objectives**

- Identify the Centers for Disease Control and Prevention (CDC) Guidelines for healthcare associated infections and multi drug resistant organisms
- Recognize the gaps between the guidelines and their current program

3. **MRSA Nasal PCR Testing: More than Pneumonia?**

*(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-011-L01-P)*

**Alaina DeKerlegand, PharmD, BCIDP**, Pharmacy Coordinator- Infectious Diseases and Antimicrobial Stewardship, Methodist University Hospital, Memphis, TN

*Dr. DeKerlegand has no relevant financial relationships to disclose.*

**Learning Objectives**

- Describe the efficacy of MRSA nasal testing for infections outside of the respiratory tract
- Identify opportunities for applying MRSA nasal testing results to de-escalation opportunities outside of the respiratory tract

4. **Challenges in C. difficile Treatment and Prophylaxis**

*(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-012-L01-P)*

**Pratish C Patel, PharmD, FIDSA, BCIDP, AAHIVP**; Program Director, Pharmacy, Vanderbilt University Medical Center, Nashville, TN

*Dr. Patel has no relevant financial relationships to disclose.*

**Learning Objectives**

- Identify when to use fecal microbiota transplant (FMT) therapy and compare between available formulations
- Determine which regimen, dose, and duration to use for secondary prophylaxis of C. difficile

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

## ROUNDTABLE SESSIONS

2:45-3:15pm (CDT) & 3:20-3:50pm CDT)

Learners may attend one(1) roundtable per session.

Capacity limits will be set for each roundtable. Please select at least one (1) back-up roundtable per session.

5. **Safeguarding Seniors: Antimicrobial Stewardship in Long-Term Care**

(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-017-L05-P)

**Quynh Dao, PharmD, BCPS, BCGP**; Clinical Consultant Pharmacist, Ampharm Inc.; Memphis, TN

*Dr. Dao has no relevant financial relationships to disclose.*

**Learning Objectives**

- Identify the seven Core Elements of Antibiotic Stewardship for Nursing Homes
- Create an actionable intervention to improve antibiotic use within nursing home setting

6. **Reframing Pregnancy Drug Labeling: Antibiotic Use and Misuse During Pregnancy and Postpartum (Risks and Benefits)**

(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-009-L01-P)

**Ashley Scism, DNP, APRN, FNP-BC**; Assistant Professor of Nursing, Gordon E. Inman College of Health Sciences & Nursing, Belmont University; Nashville, Tennessee

*Dr. Scism has no relevant financial relationships to disclose.*

**Learning Objectives**

- Describe how the Pregnancy and Lactation Labeling Rule (PLLR) alters and improves the information provided about medication use during pregnancy compared to the previous letter categories
- Facilitate patient-centered counseling using PLLR information

7. **Candida auris: Impact on Nursing in the Acute Care Setting**

(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-021-L05-P)

**Kate Derveloy, MSN-HSM, BA, RN**; Infection Preventionist III, Methodist LeBonheur Healthcare, Methodist University Hospital, Memphis TN

*Ms. Derveloy has no relevant financial relationships to disclose.*

**Learning Objectives**

- Recall information about C.auris that can be shared to educate patients and their families
- List 3 mitigation strategies to reduce cross-contamination of C.auris in the in-patient setting

8. **"Getting Better" - Top 10 Papers of 2023**

(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-0000-24-022-L01-P)

**Joshua Stripling, MD**; Associate Professor, Director, Antimicrobial Stewardship, Division of Infectious Diseases; Heersink School of Medicine, The University of Alabama at Birmingham

*Dr. Stripling has no relevant financial relationships to disclose.*

**Learning Objectives**

- Recall clinically relevant literature from 2023 relating to infection prevention and antimicrobial stewardship practices
- Recognize the optimal antibiotics for use in patients with reported beta-lactum allergies

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)



## Policies for Refunds and Cancellations

**Refund Policy:** If you need to cancel your registration, please notify us as soon as possible by emailing [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu). No refunds will be given for cancellations on or after May 5, 2024. Cancellations prior to May 5, 2024, will receive a refund minus a \$50 processing fee.

**Cancellation Policy:** In the rare event this event is cancelled, registrants will receive a full refund.

## Requirements for Successful Completion of the CE Activities and Awarding of Credit

To be eligible for the awarding of CE credit (contact hours) for any session, each participant **must**:

- [register to attend the Symposium](#);
- attend 100% of the session for which they are seeking contact hours;
- actively participate in the discussions, engagement activities, and live assessment (poll) questions of the session for which they are seeking contact hours; and
- complete the electronic activity evaluation for the session for which they are seeking contact hours.

**Pharmacist Attendees:** Your CE credits will be automatically submitted to NABP CPE Monitor upon successful completion of the online activity evaluation. Instructions for completing the evaluation will be emailed to the address provided to Belmont at the time of registration. Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/help/>.

To receive credit for your participation, you must include your NABP ePID and Month/Day in your Belmont LMS account profile. Your credit(s) will **not** transfer to CPE Monitor without this information. It is the responsibility of the pharmacist to notify Belmont if their credit isn't posted to CPE Monitor within 48 hours of completing the activity evaluation.



Belmont University College of Pharmacy & Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These knowledge-based activities for pharmacists will provide up to 5.25 contact hours (0.525 CEUs) of live continuing education credit to pharmacists who register to attend the Symposium, attend 100% of a session per time slot, actively participate in the engagement activities of each session attended, and complete the online activity evaluation for each activity attended.

**Nurse Attendees:** Each course in this activity is accredited for *AMA PRA Category 1 Credit™*. We recommend that you check with your individual licensing board to confirm acceptance.



**Physician Attendees:** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Tennessee Medical Association and Belmont University College of Pharmacy & Health Sciences. The Tennessee Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Tennessee Medical Association designates this live activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)